Background
Despite potential adverse-events in a pediatric population,
corticosteroids (CS) are used to induce remission in pediatric
Crohn’s disease. Exclusive enteral nutrition (EEN) also induces
remission, but is infrequently used in the United States because CS is
considered the superior therapy. New data have become available since the
publication of the most recent meta-analysis in 2007.
Methods
All studies with comparator arms of EEN and an exclusive CS, with
remission clearly defined were identified. Online bibliographic databases
including MEDLINE, EMBASE, Web of Science, Cochrane Databases, Open Grey,
Grey Lit, Clinicaltrials.gov, and the WHO lists of
clinical trials were searched.
Results
Of 2795 identified sources, nine studies met our inclusion criteria.
Eight of these (n=451), had data that could be abstracted into our
meta-analysis. EEN was as effective as CS in inducing remission
(OR=1.26 [95% CI 0.77, 2.05] in pediatric
Crohn’s disease. There was no difference between EEN and CS efficacy
when comparing newly diagnosed Crohn’s (OR = 1.61 [
95% CI 0.87, 2.98]) or relapsed (OR = 0.76
[95% CI 0.29–1.98]). Intestinal healing was
significantly more likely among patients receiving EEN compared to CS
(OR=4.5 [95% CI 1.64, 12.32]). There was no
difference in the frequency of biomarker normalization including CRP
(OR=.85 [.44, 1.67]) and fecal calprotectin (OR 2.79
[95% CI 0.79–10.90]).
Conclusion
There is no difference in efficacy between EEN and CS in induction of
remission in Crohn’s disease in a pediatric population. Exploratory
analyses suggest that a greater proportion of patients treated with EEN
achieved mucosal healing.